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Abstract
 
Respiratory infections are the third leading cause of death worldwide. Illness is caused by
pathogen replication and disruption of airway homeostasis by excessive expansion of cell numbers.
One strategy to prevent lung immune–mediated damage involves reducing the cellular burden.
To date, antiinflammatory strategies have affected both antigen-specific and naive immune
repertoires. Here we report a novel form of immune intervention that specifically targets recently
activated T cells alone. OX40 (CD134) is absent on naive T cells but up-regulated 1–2 d after
antigen activation. OX40–immunoglobulin fusion proteins block the interaction of OX40
with its ligand on antigen-presenting cells and eliminate weight loss and cachexia without pre-
venting virus clearance. Reduced proliferation and enhanced apoptosis of lung cells accompanied
the improved clinical phenotype. Manipulation of this late costimulatory pathway has clear
therapeutic potential for the treatment of dysregulated lung immune responses.
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Introduction
 
According to the World Health Organization lower respi-
ratory tract infections are the third most common cause of
death (1). Influenza virus is a causative agent of both epidemic
and pandemic respiratory viral illness with over 26,000
deaths attributed to the last outbreak in Britain alone (2).
Though pivotal for viral clearance, over exuberant T cell
responses result in airway occlusion (3, 4) and contribute
significantly to pathology (5). Therefore, in the absence of
universal vaccine candidates, inhibition of inflammatory T
cells presents a novel strategy for therapeutic intervention
in the treatment of influenza virus infection.
Several processes could be inhibited to thwart T cell
proliferation including a reduction of antigen presentation
by MHC, inhibition of costimulatory B7 molecules, or
depletion of T cells themselves. Such strategies, however,
affect both bystander and antigen-activated T cell reper-
toires. A more definitive approach would selectively inhibit
only those T cells recently activated by antigen. OX40
(CD134) is an ideal candidate because unlike CD28, it is
absent on naive T cells but up-regulated 1–2 d after antigen
encounter (6). OX40 imparts a survival signal to the T cell
preventing activation-induced cell death (7) but up-regulating
anti-apoptosis gene expression (8) and cytokine production
(9). Similarly, OX40 ligand (OX40L) is expressed only at
low levels on resting APCs and is up-regulated after
CD40–CD40L interactions (6, 10).
The critical role for OX40 is revealed in OX40-deficient
mice where CD4
 
  
 
T cell responses are abrogated during
both Th1-driven responses to viral infection (11) and
Th2-dominated allergic inflammation (12). Furthermore,
inhibition of OX40 using soluble OX40 fusion proteins
or antibody abrogates the detrimental effects of colitis in
SCID mice (13), inflammatory bowel disease (14), and aller-
gic encephalomyelitis (15).
Manipulation of this late costimulatory pathway has not
been tested during virus-induced inflammation. We show
that interruption of OX40/OX40L with an OX40–Ig fusion
protein ameliorates influenza-driven T cell immunopathology
and associated illness without preventing viral clearance. This
beneficial outcome is directly linked to a reduced inflam-
matory infiltrate caused by an inhibition of proliferation
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Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage fluid; BrdU,
5-bromo-2
 
 
 
-deoxyuridine; HA, hemagglutinin; MLN, mediastinal LN;
OX40L, OX40 ligand; RT, room temperature.T
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and enhanced apoptosis. These findings show that OX40
costimulation plays a pivotal role in immunopathology to
respiratory viral infection and highlights a novel therapeutic
approach for the treatment of influenza-induced disease.
 
Materials and Methods
 
Mice and Virus.
 
8–12-wk-old female BALB/c (Harlan Olac
Ltd.) were kept in pathogen-free conditions according to Home
Office guidelines. Influenza A strain X31 (hemagglutinin [HA] ti-
tre 1024) was provided by A. Douglas (National Institute for
Medical Research, London, United Kingdom).
 
Production of OX40 Fusion Proteins.
 
The generation of murine
OX40–mIgG1 fusion protein (OX40–Ig) and the OX40–IgG4
fusion protein containing a mutation of Leu (235) to Glu in the
Fc region of IgG4 has been previously described (15, 16). Con-
structs were deemed LPS-free by gas chromatography-mass spec-
trometry of fatty acid methyl esters. In brief, samples were deriva-
tized using methanolic HCl and resulting fatty acid methyl esters
dissolved in hexanes before column injection on a Stabilwax col-
umn (30 m 
 
  
 
0.25 mm internal diameter; Restek Corp.). Sam-
ples were analyzed using a temperature gradient of 150–250
 
 
 
C at
a rate of 3
 
 
 
C/min. Characteristic retention times and spectra of
known standards were used to identify any fatty acid methyl esters
present in the samples.
 
Mouse Infections and Treatment.
 
On day 0 mice were anesthe-
tized and intranasally infected with 50 HA units influenza virus.
Mice were injected i.p. with 100 
 
 
 
g OX40–Ig fusion protein (Xen-
ova Pharmaceuticals) or mouse IgG (Caltag) on alternate days. The
weight of mice was monitored daily and illness severity was scored
as follows: 0, healthy; 1, barely ruffled fur; 2, ruffled fur but active;
3, ruffled fur and inactive; 4, ruffled fur, inactive, and hunched; 5,
dead. Mice were killed on various days after infection by injection
of 3 mg pentobarbitone and exsanguinated via the femoral vessels.
Some mice were challenged with 50 HA units influenza virus 3 wk
later and killed on various days as indicated in the text.
 
Cell Recovery and Flow Cytometry.
 
Single cell suspensions
from bronchoalveolar lavage fluid (BAL), lung tissue, and medias-
tinal LNs (MLNs) were stained for surface markers and intracellu-
 
lar cytokines and analyzed by flow cytometry as previously de-
scribed (17). All antibodies were purchased from BD Biosciences
except anti–OX40-FITC (Serotec). Influenza-specific CD8
 
  
 
T
cells were identified using an APC-labeled MHC class I tetramer
(H-2
 
d
 
) loaded with the immunodominant peptide TYQR-
TRALV from the influenza nucleoprotein (National Institute of
Allergy and Infectious Diseases Tetramer Facility). For apoptosis
analysis, binding of PE-labeled annexin V was detected according
to the manufacturer’s instructions. All data were acquired on a
FACSCalibur™ and 30,000 lymphocyte events were analyzed
with CELLQuest™ Pro software (BD Biosciences).
 
5-bromo-2
 
 
 
-deoxyuridine (BrdU) Labeling and Detection.
 
Mice
were treated with 0.8 mg/ml BrdU (Sigma-Aldrich) in their
drinking water for 4 d. MLNs were taken and cells were stained
with CyChrome anti-CD4 and anti–CD8-PE as previously de-
scribed (17). After washing, cells were resuspended in 500 
 
 
 
l ice-
cold 0.15 M NaCl. While mixing gently, 1,200 
 
 
 
l ice-cold 95%
ethanol was added drop-wise. Cells were incubated at 4
 
 
 
C in the
dark for 30 min before washing with cold PBS and fixing for 30
min at room temperature (RT) with 1% paraformaldehyde and
0.01% Tween-20. Cells were then centrifuged and incubated
with 50 U DNase I (Sigma-Aldrich) in 4.2 mM MgCl
 
2
 
, 0.15 M
NaCl, pH 5.0, for 10 min at RT. After centrifugation, cells were
incubated in the dark at RT for 30 min with FITC anti-BrdU
(BD Biosciences), washed in PBS/3%BSA/0.01% sodium azide,
and analyzed on a FACSCalibur™. Lymphocytes positive for
FITC anti-BrdU were detected with CELLQuest™ Software
(BD Biosciences) and were identified to have undergone postthy-
mic proliferation (18).
 
Lung Influenza Titer.
 
Clearance of influenza was assessed in
lung homogenates 2, 4, 7, and 11 d after virus challenge. Homog-
enized cells were freeze thawed three times, centrifuged at 4,000 
 
g
 
,
and supernatants were titrated in doubling dilutions on Madin
Darby canine kidney cell monolayers in flat-bottomed 96-well
plates. After incubation at RT for 3 h, samples were overlaid with
methylcellulose and incubated for 72 h at 37
 
 
 
C. Cell monolayers
were washed and incubated with anti-influenza antibody (Sero-
tec), followed by anti–mouse–horseradish peroxidase (Dako-
Cytomation) and infected cells were detected using 3-amino-9-
ethylcarbazole (AEC; Sigma-Aldrich). Infectious units were
Figure 1. Influenza infection induces weight
loss, pulmonary inflammation, and OX40 ex-
pression by T cells. (A) Mice were infected
with influenza, BAL removed 2, 4, 7, 11, and
15 d after infection, and total viable cells were
enumerated (right axis). Weight loss was moni-
tored daily and expressed as percent of original
body weight (left axis). Results represent mean
values   SEM from four mice per group. BAL
(B and C) and MLNs (D and E) were removed
from influenza-infected mice and cells were
stained with OX40-FITC and APC-CD4 (B
and D) or PercP-CD8 (C and E). Results repre-
sent the mean percent (left) and total number
(right) of OX40  T cells   SEM from five indi-
vidual mice and is representative of three separate
experiments.T
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enumerated by light microscopy and total plaque-forming units
per lung were quantified (number of plaques 
 
  
 
dilution factor 
 
 
 
total volume of lung homogenate).
 
Statistics.
 
Statistical significance was evaluated using a two-
tailed Student’s 
 
t
 
 test assuming unequal variance with the Minitab
software program. Where more than one comparison was made
within an experiment, the Bonferroni correction was applied.
 
Results and Discussion
 
OX40–Ig Treatment Reduces Influenza-induced Weight Loss
and Exuberant T Cell Inflammation During Infection.
 
Intra-
nasal influenza virus infection results in rapid accumulation
of lymphocytes within the lung and airways (4). Maximal T
cell expansion at 7 d coincides with peak weight loss (Fig. 1
A). The association between cellular infiltration and weight
loss is characteristic of many lung viral infections (19, 20).
The kinetics of OX40 expression by BAL CD4
 
  
 
(Fig. 1 B)
and CD8
 
  
 
(Fig. 1 C) T cells followed a similar pattern in
that the highest proportion was present 4 d after influenza
infection. This profile was also evident in the lung (unpub-
lished data). By calculating the total number of CD4
 
 
 
OX40
 
  
 
and CD8
 
  
 
OX40
 
  
 
T cells the highest numbers co-
incided with maximum weight loss at day 7. OX40 expres-
sion was also present in the lung-draining MLN. The pro-
portion and total numbers of OX40-expressing CD4
 
  
 
(Fig.
1 D) and CD8
 
  
 
(Fig. 1 E) T cells peaked at 4 d.
Because excess T cell infiltration into the virally infected
lung compromises lung function and compliance, we next
examined the effect of reducing T cell costimulation via
OX40. Control-treated mice lost 
 
 
 
25% of their initial body
weight, whereas those treated with OX40–Ig did not (Fig. 2
A). Visual inspection revealed that control-treated, influ-
enza-infected mice, especially at day 6, appeared hunched,
immobile, and severely cachexic, whereas OX40–Ig-treated
mice were consistently indistinguishable from uninfected
controls (Fig. 2 B). The striking elimination of weight loss
and illness severity was accompanied by a reduction in pul-
monary inflammation including neutrophils (unpublished
data) and CD4
 
  
 
and CD8
 
  
 
T cells (Fig. 2 C). The total
number of OX40-expressing T cells was also reduced in
line with the general reduction in inflammation (unpub-
lished data). However, the percent of T cells expressing
OX40 was unaffected. This was not surprising because
OX40 expression is induced by CD28 and TCR signals and
does not rely on interaction with OX40L. OX40L expres-
sion has been observed on some T cells cultured in vitro
(21). Although reduced T cell numbers in our study may
reflect depletion after OX40–Ig binding, we do not believe
this to be the case because OX40–Ig did not enhance T cell
death in vitro (unpublished data) and an alternative OX40–
Ig fusion that does not fix complement or promote ADCC
produced an identical effect (Fig. 2 D). The benefit of ma-
nipulating OX40 costimulation is clearly evident in hema-
toxylin and eosin–stained sections of lung tissue. Cellular in-
filtration around the airways and blood vessels was markedly
reduced in OX40–Ig-treated mice compared with control
IgG–treated mice (Fig. 2, E and F, respectively).
Using flow cytometry and intracellular cytokine staining,
the number and proportion of CD8
 
  
 
T cells producing
TNF were found to be reduced in OX40–Ig-treated mice
(Fig. 3, A and B). Tetramer-binding CD8
 
  
 
T cells (Fig. 3,
C and E) and their production of TNF (Fig. 3 D) were se-
verely reduced by OX40–Ig treatment. Although TNF is
greatly increased systemically in some viral infections, we
did not observe elevated serum TNF by ELISA or cyto-
metric bead array after influenza virus infection (unpub-
lished data). Anti-TNF antibodies reduce weight loss and
cell recruitment during influenza infection (5). Precisely
Figure 2. OX40–Ig treatment
prevents illness and T cell inflamma-
tion during influenza infection. (A)
BALB/c mice (n   4) were infected
with influenza, treated with mouse
IgG or OX40–Ig on alternate days,
and weight loss was monitored and
expressed as percent of original
weight (P   0.05 days 2–6). Illness
was scored from 1–5 based on the
degree of immobility, cachexia, and
ruffled fur. The cumulative illness
score was calculated by treatment
group (B). (C) Total numbers of
BAL CD4  and CD8  T cells 6 d
after infection were determined by
multiplying the percent of positive
cells by flow cytometry with the total
viable cells recovered from the BAL
of IgG or OX40–Ig-treated mice.
(D) In an identical experiment, BAL
CD4   and CD8   T cell numbers
were determined in mice treated
with IgG, OX40–Ig, and OX40–
mutIgG (gray symbols). Open symbols, OX40–Ig-treated mice; closed symbols, control IgG–treated mice. E and F show representative hematoxylin and
eosin–stained lung sections 7 d after influenza infection in OX40–Ig- (E) or IgG- (F) treated mice. All experiments were repeated two to three times
with five mice per group.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
Reduced Costimulation Prevents Lung Immunopathology
 
1240
how this works, however, is unclear. Influenza virus repli-
cation is restricted to the respiratory epithelium. In this sit-
uation we believe that TNF indirectly causes weight loss by
enhancing cell recruitment and proliferation leading to air-
way occlusion. These results imply that OX40 signaling
plays a critical role during T cell–mediated immunopathol-
ogy elicited by influenza infection.
 
Delayed OX40–Ig Treatment Inhibits Weight Loss in In-
fluenza-infected Mice with Established Illness and Does Not
Affect Viral Clearance or Recall Responses.
 
Next, we delayed
OX40–Ig treatment during influenza virus infection until
the mice had lost 20% of their original weight. Such de-
layed treatment still reversed the decline of weight com-
pared with controls (Fig. 4 A; P 
 
  
 
0.05 days 5–7) and mice
appeared perfectly healthy. Plaque assays performed on
lung homogenates in a time course study did not reveal any
delay in influenza virus clearance when OX40–Ig was ad-
ministered on day 0 (Fig. 4 B) or 3 d after infection (un-
published data).
The rather surprising lack of an effect of OX40–Ig on
virus clearance might be partially explained by stimulation
of B cells. OX40 interaction with OX40L imparts a bidi-
rectional signal to the T cell and the APC (22). Although
soluble OX40 fusion proteins reduce the signal to the T
cell, signaling to the APC remains intact and may even be
enhanced. OX40–Ig treatment may therefore induce anti-
Figure 3. OX40–Ig reduces TNF and tetramer
binding of CD8  T cells. (A) Influenza-infected
mice were treated with IgG or OX40–Ig and
lung cells were stained for CD8 and intracellular
TNF. Total numbers were calculated by multi-
plying total viable cells by the percent of CD8 /
TNF  cells. Mean percent (left) and total numbers
(right)    SEM from five mice per group are
shown. Representative plots of lung CD8 versus
TNF in lymphocytes 7 d after infection in
IgG- (left) or OX40–Ig- (right) treated mice
(B). (C and E) Lung cells were removed from
IgG- or OX40–Ig-treated, influenza-infected
mice 0, 2, 5, 7, and 10 d after infection and
stained with anti–CD8-PercP, tetramer-APC,
and anti–TNF-FITC. Total numbers were cal-
culated by total viable cells   percent CD8 /
Tetramer  (C) or CD8 /Tetramer /TNF  (D).
Results are mean values   SEM of five mice per
group. Representative plots of CD8 versus
tetramer  are shown in E in IgG- (left) or
OX40–Ig- (right) treated mice 7 d after infection.
All results are representative of at least two inde-
pendent experiments containing five mice per
group. Open symbols, OX40–Ig-treated mice;
closed symbols, IgG-treated mice.
Figure 4. OX40–Ig reduces established illness
and T cell proliferation, increases apoptosis, but
does not inhibit viral clearance or recall responses.
(A) Mice (n   3) were infected with influenza
virus on day 0 and treated with IgG or OX40–Ig
on days 3, 4, and 5 after infection. Weight loss is
expressed as percent of original weight. (B) Mice
(n     4) were infected with influenza and
treated with either IgG or OX40–Ig. On days
2, 5, 7, and 11 after infection, lung tissue was
homogenized and viral titre was quantified by
plaque assay. (C–E) Mice (n   4) were infected
with influenza and treated with IgG or OX40–
Ig as in B. 3 wk later mice were challenged with
influenza and on days 2, 5, and 7 after infection,
CD4  (C), CD8  (D), and CD8  tetramer  (E)
T cells were enumerated in lung tissue. (F and
G) Proliferating MLN CD4 and CD8 T cells
(F, by BrdU incorporation) and apoptotic annexin
V–stained lung cells (G) were assessed in control-
or OX40–Ig-treated mice 4 and 7 d, respectively,
after influenza infection. Closed symbols, IgG
control; open symbols, OX40–Ig. Mean
values   SEM are shown and are representa-
tive of two separate experiments.T
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viral antibodies and elicit compensatory effects. However,
analysis of influenza-specific antibody 4, 7, 11, 15, and 19 d
after infection showed no differences in nasal IgA responses
or serum IgG1 and IgG2a (unpublished data).
The ability of mice to respond to reinfection was not af-
fected by OX40–Ig treatment despite the significant re-
duction in T cell immunity during the first infection. A
time course analysis after rechallenge did not reveal any
statistical differences between the numbers of CD4
 
  
 
(Fig.
4 C) or CD8
 
  
 
(Fig. 4 D) T cells and those binding MHC
class I tetramer (Fig. 4 E). In both OX40–Ig-treated and
control mice influenza virus was cleared 5 d after rechal-
lenge. On day 2, virus titres were similar (1,080 
 
  
 
288 for
control and 1,546 
 
  
 
246 plaque-forming units/lung in the
OX40–Ig-treated group). The lack of an effect on recall
responses is surprising and may suggest that sufficient im-
mune memory was generated during the first infection.
Influenza virus promotes a very large inflammatory re-
sponse. It is likely that not all of the inflammatory cells are
required to contain infection. The reduced inflammatory
infiltrate may therefore still contain enough cells to seed
the memory pool. No studies to date have addressed the
number of antigen-specific cells required to eliminate a vi-
ral infection. In this study we show that a threefold reduc-
tion in T cells remains efficient and does not cause disease.
Alternatively, efficient rechallenge responses may reflect
recruitment of naive cells or the fact that OX40–Ig treat-
ment was only administered to day 10 during the first in-
fection. After day 10 some memory T cell responses may
have been generated.
 
Impaired T Cell Responses in OX40–Ig-treated Mice Is a
Consequence of Reduced Proliferation and Enhanced Apoptosis.
 
The reduction of T cells by OX40–Ig could represent re-
duced proliferation or increased apoptosis. Rather than ar-
tificially examining proliferation in vitro, we gave mice
BrdU in their drinking water during infection. BrdU is in-
corporated into proliferating cells and can be detected by
flow cytometry using an anti-BrdU antibody. Analysis of
MLN cells 4 d after infection revealed that OX40–Ig treat-
ment had significantly reduced both CD4
 
  
 
and CD8
 
  
 
T
cell proliferation (Fig. 4 F). This effect was only observed at
the peak of proliferation and not during the later stages of
infection (unpublished data).
OX40 binding to its ligand induces the anti-apoptotic
proteins Bcl-2 and Bcl-xL (8) and prevents activation-
induced cell death (23). Reduced T cell numbers in OX40–
Ig-treated mice may therefore result from increased cell
death. The frequency of apoptotic CD4
 
  
 
and CD8
 
  
 
T cells
was identified by annexin V staining and flow cytometry.
Administration of OX40–Ig significantly enhanced the pro-
portion of apoptotic CD4
 
  
 
(Fig. 4 G) but not CD8
 
  
 
T cells
(unpublished data) in the airways during the later stages of
infection (days 7 and 10), implying that OX40 costimula-
tion is required to prolong pulmonary T cell survival.
The reduction in T cell infiltrate is similar to that ob-
served in influenza virus–infected OX40
 
 
 
/
 
  
 
mice (11).
Using such mice it is difficult to ascertain whether the
improved outcome is due to reduced T cell function or
an alteration of APC activation through OX40L. Our
studies compliment and extend this in several important
ways: (a) we show that both CD4
 
  
 
and CD8
 
  
 
T cells are
affected, (b) that inflammatory cytokines are reduced,
and (c) that proliferation is reduced and cell death in-
creased.
The reduction of both T cell numbers and proinflamma-
tory cytokine secretion after OX40–Ig treatment raises the
question of why lung viral replication is still effectively
controlled? There are three plausible explanations: (a) in-
nate immune mechanisms such as NK cells, which were
not affected by OX40–Ig treatment (unpublished data),
may mediate viral clearance. However, the role of NK cells
in immunity to influenza virus infection is unclear. In-
creased susceptibility to influenza virus in the senescence-
accelerated mouse is associated with impaired activity of
NK cells, but CD8
 
  
 
T cells are also defective in this model
(24). (b) Influenza virus is highly inflammatory and a mod-
erate reduction in the vigor of the inflammatory response
might be beneficial without affecting virus clearance. This
hypothesis is consistent with the efficient control of other
viruses in OX40 knockout mice (25, 11). (c) Because
OX40 is expressed 1–2 d after antigen activation, influenza
virus infection might be controlled by earlier T cell–APC
interactions.
The delayed expression of OX40 makes it an ideal target
during immunopathological conditions because it enables
initial T cell priming and containment of viral replication.
In contrast, blockade of CD28, which is constitutively ex-
pressed by T cells, significantly delays influenza clearance
(26). The lung microenvironment requires careful immune
homeostasis. Excessive inflammation compromises gaseous
exchange by occluding the airways and inducing mucus
production. This is more apparent in the lungs than other
mucosal sites. The gut, for example, can accommodate rel-
atively large cell numbers while retaining its primary func-
tion. Evidence from murine models suggests that a re-
duction, but not elimination, of the lung inflammatory
infiltrate is beneficial. Depletion of inflammatory cytokines
(5), CD4
 
  
 
or CD8
 
  
 
T cells, or T cell subsets (27) all reduce
weight loss without preventing virus clearance. Collec-
tively, this implies that the problem is caused by the num-
ber of T cells present and not their phenotype. Manipula-
tion of OX40 therefore presents a novel therapeutic
strategy for treatment of immunopathological conditions
by reducing the number of activated T cells while leaving
the naive repertoire intact.
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